Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
eu HORIZON-MISS-2027-02-CANCER-02 · Horizon Europe (HORIZON)
| Status | forthcoming |
|---|---|
| Opens | 10 Feb 2027 |
| Deadline | 21 Sep 2027 — 373 days |
| Action | HORIZON Innovation Actions |
| Official page | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunit… |
| Fetched | 2026-09-12 04:00:03+00:00 |
You are reading one call. 1,385 are open right now.
A search matches words. It cannot know what your institution works on. Give the name and every open call is ranked against it — this one included.
Free · no account · nothing stored that identifies youScope
Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Patients afflicted by lung, bowel, breast or prostate cancer [1] , will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures [2] . Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators [3] will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer. National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer. Scope: Lung, bowel, breast and prostate cancer incidence, mortality and prevalence across EU Member States and Associated Countries are increasing while showing substantial variation, with Central and Eastern European communities, regions and countries particularly affected [4] . At the same time, the level of development of comprehensive cancer infrastructures continues to vary considerably across EU Member States and Associated Countries, contributing to inequalities, in particular in terms of clinical research capacity as well as quality of and access to innovative diagnostic and therapeutic interventions. Applicants should address all of the following: Comprehensive cancer infrastructures across the EU Member States and Associated Countries come together to conduct clinical research on lung, bowel, breast or prostate cancer focusing on at least one of the following areas: Innovative diagnostics; Radiotherapy, surgery, chemotherapy; Therapeutic cancer vaccines for the treatment of cancer patients with early-stage, advanced, metastatic or minimal residual disease (e.g. after debulking by surgery, chemotherapy, radiotherapy, or immunotherapy); Implementation of appropriate clinical practice guidelines for diagnosis and treatment in countries without or with limited Comprehensive Cancer Infrastructures; Comprehensive cancer infrastructures should extensively pil…
What consortia for this call have looked like
4 projects
have been funded under this line
(HORIZON-MISS-CANCER-02) in Horizon Europe and H2020. This is what they
were made of — not a recommendation, just what the Commission signed.
range 7–21
19 seen across all of them
across those projects
The mix of organisations
Who coordinated them
Coordinating an EU project is a demanding, specific job. These organisations have done it on this topic line before.
This is the shape, not the consortium. It says how many partners these projects had and what kinds of organisation were in them. It does not know whether your idea needs the same mix, who is available, who is already committed elsewhere, or how the work and the budget should be divided. Those are judgement calls on a specific proposal, and no amount of public data answers them.
Building the actual consortium — finding the partners, agreeing the roles, and writing it so it survives an evaluation — is what Scientific Network Management does. Free either way; the radar does not change if you never ask.
Finding the call is the easy half. Scientific Network Management is the grant-writing practice behind this radar — 13 years of writing and managing EU-funded research projects, including two EuropeAid technical assistance contracts building biotechnology centres in Türkiye as Team Leader.
Talk to us What SNM does No obligation, and nothing here is conditional on using us — the radar stays free and complete either way.